

GLMN causing vascular malformations: the clinical and genetic differentiation of cutaneous venous malformations

Mollie Helena McMahon,¹ Nasim Tahir,² Meena Balasubramanian^{3,4}

¹Department of Paediatrics, Sheffield Children's Hospital, Sheffield, UK

²Department of Paediatric Radiology, Leeds Children's Hospital, Leeds, UK

³Oncology & Metabolism, University of Sheffield, Sheffield, UK

⁴Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK

Correspondence to

Dr Meena Balasubramanian; m.balasubramanian@sheffield.ac.uk

Accepted 7 June 2022

SUMMARY

Cutaneous venous malformations frequently present with blue-pink lesions on the skin or mucosal surfaces. They can be problematic for patients who experience pain or unsightly lesions and can also be associated with significant bleeding. A proportion of venous malformations have been noted to occur in families, in particular glomuvenous malformations (GVMs). A 'two-hit' occurrence of genetic pathogenic variants appears to explain the appearance of GVMs, with the initial change in the germline copy of *GLMN* followed by a second somatic hit. Here we discuss a report of siblings experiencing such lesions, which were diagnosed as GVMs by genetic testing. We include a review of the literature regarding the clinical and genetic differences between these groups of venous malformations.

BACKGROUND

Vascular anomalies often present in a variety of ways to paediatricians and adult physicians, from mild innocuous lesions to sources of profound bleeding or local intravascular coagulopathy. Differentiating between the types can be a diagnostic challenge. Recent advances in identifying the causative genes and genetic processes involved have helped to establish inheritance patterns allowing afflicted families a degree of understanding of the prognosis of their condition.

Vascular anomalies include vascular malformations and vascular tumours. Vascular tumours develop due to endothelial cell proliferation. They typically regress with the patient's age, in contrast to vascular malformations, which progress with age and never regress on their own.¹



Figure 1 Lesion on the dorsum of the younger brother's foot.



Figure 2 Lesions on the lateral aspect of the younger brother's foot.

Vascular malformations represent structural defects in vascular development.^{2,3} All are present from birth although they may not become clinically apparent until adulthood and are life-long. They appear as blue to purple, sometimes tender lesions. Vascular malformations can be high or low flow, with high flow being from arterial or arterio-venous fistulas and low flow being from capillary, venous or lymphatic systems. Venous malformations are the most common group overall.

Venous malformations can be subdivided into various types with differences in clinical features and inheritance pattern. The International Society for the Study of Vascular Anomalies (ISSVA) devised a classification system which has been widely adopted (most recently updated in 2018).⁴ The venous malformations are subdivided into sporadic (or common) venous malformation, cutaneomucosal venous malformation, cerebral cavernous malformation, glomuvenous malformation, verrucous malformation and intraosseous malformation. The blue rubber bleb nevus syndrome (sometimes known as the 'bean' syndrome) is another group.

In a patient with multiple cutaneous venous malformations, the possible diagnoses include sporadic venous malformation, cutaneomucosal venous malformation, glomuvenous malformation and blue rubber bleb nevus syndrome. We will be focusing on these groups in this report.

Glomuvenous malformations (GVMs) have historically been known as 'glomangiomas'.⁵ GVMs classically have a blue-purple or pink cobblestone raised appearance and are hard and tender on palpation, they do not compress easily. They are usually present peripherally and rarely on the mucosa. The lesions usually develop in childhood and are



© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: McMahon MH, Tahir N, Balasubramanian M. *BMJ Case Rep* 2022;**15**:e246114. doi:10.1136/bcr-2021-246114



Figure 3 Direct venogram of the abnormal veins (red circles) using needles punctured into them. These needles are then used to inject sclerosant for treatment.

life-long, although more lesions may develop later, usually by the third decade.⁶ Histologically, GVMs have defects in the smooth muscle cell layer with characteristic round ‘glomus cells’ which are adjacent to the distended vascular channels.^{2,4} These glomus cells have a thermoregulatory role, their exact cellular aetiology is not known, but immunohistochemistry and electron microscopy suggest they are modified smooth muscle or pericyte cells.⁷ GVMs can be treated by surgical excision, partial excision or by sclerotherapy.⁵ Unlike other venous malformations compressive stockings are not recommended as they worsen the pain.

Blue rubber bleb nevus syndrome can involve both cutaneous and visceral lesions; therefore, unlike GVMs, it is associated with gastrointestinal lesions leading to severe iron deficiency anaemia.⁸ The cutaneous lesions are small, rubbery and easily compressible, often affecting the palms and soles.

Cutaneomucosal venous malformations usually appear in the cervicofacial region and are always blue.⁹ Although usually on the skin, cutaneomucosal malformations can involve the skeletal muscle, gastrointestinal tract, and other organs.⁹ Histologically, the defect in cutaneomucosal venous malformations and blue




Figure 4 Axial, coronal and sagittal postcontrast MRI of the foot showing abnormal veins at the lateral aspect of the foot (blue circles).

rubber bleb nevus syndrome is related to vascular smooth muscle cell recruitment.⁸ In both conditions, there is an associated risk of associated consumptive coagulopathy and profound iron deficiency anaemia, and patients require investigations looking for anaemia and coagulopathies. Sporadic venous malformations can be isolated or multiple, occur in the same regions, and are clinically similar to cutaneomucosal venous malformations.

Although clinical differentiation of the types of venous malformations is possible, it can be challenging. Imaging such as ultrasound and MRI are used to provide more detail on the size and flow of the lesion.⁸ D-dimers can point towards GVMs if not elevated.¹⁰ Histology may give a diagnosis of GVM, especially if cuboid glomus cells are seen; however, they are not present in all lesions.⁵

Genetics have been able to provide support in identifying those lesions where other diagnostic testing cannot help.

Here, we describe a report of siblings with cutaneous vascular abnormalities in which genetic testing was required to reach a diagnosis.

CASE PRESENTATION

Two siblings were referred to the clinical genetics service due to blue lesions noted on their extremities. The older brother was in his early teens and had blue-purple naevi on his left foot. He had no associated pain or discomfort from the lesions, and they did not bleed. His younger brother had more significant lesions on the right foot, affecting the lateral side and base, which were painful (see figures 1 and 2). He also had a similar lesion on his lower back, which did not cause discomfort. Both boys were otherwise fit and well and had been born at full term via normal delivery.

Their parents were fit and well and did not have any lesions.

The younger brother had initially been seen by a specialist radiologist and, at age 6 years, had received sclerotherapy for the painful foot lesions (see figures 3 and 4). At this time, the presumptive diagnosis was glomovenous tumour. However, the clinical genetics team raised the possibility of blue rubber bleb nevus syndrome as a likely diagnosis. Due to the potential complications of consumptive coagulopathy, iron deficiency anaemia and gastrointestinal tract malformations, the boys were

Table 1 Summary of venous malformations

	Symptoms	Gene pathway	Inheritance
GVM	Painful on compression, not associated with significant bleeding complications	<i>GLMN</i>	Germline variant plus second somatic variant in the other allele
Cutaneomucosal	Associated with bleeding complications, iron deficiency anaemia, coagulopathy	<i>TEK</i>	Germline variant with or without second somatic variant in same or other allele
Sporadic	Associated with bleeding complications, iron deficiency anaemia, coagulopathy	<i>TEK</i> <i>PIK3CA</i> in 20% of unifocal	No germline mutation Unifocal one somatic mutation Multifocal two somatic mutations (mosaic somatic +later somatic in single allele)
BRBN	Associated with bleeding complications, iron deficiency anaemia, coagulopathy	<i>TEK</i>	Double variant in single <i>TEK</i> allele

BRBN, blue rubber bleb nevus; GVM, glomovenous malformation.

referred to haematology for further investigations. They were both found to have normal clotting profiles and blood films.

OUTCOME AND FOLLOW-UP

The brothers were diagnosed with GVMs following genetic testing. Genomic DNA from blood samples of both brothers were sent for targeted vascular skin disorders gene panel testing and revealed that they were heterozygous for a pathogenic NM_053274.2 *GLMN* c.108C>A,p.Cys36* nonsense variant (glomulin gene) (MIM 601749).¹¹ This variant was first reported to lead to GVMs (MIM 138000) by the Brouillard group in 2002.^{12 13} It is predicted to introduce a stop codon, leading to premature truncation of the protein. The ACMG evidence used for classification of variants included PVS1_very strong (predicted to introduce a stop codon leading to premature truncation of protein); PS4_moderate (reported in the literature multiple times as being associated with GVMs); PM2_moderate (present at low frequency in the gnomAD population database).¹⁴

The family have been informed and reassured that there are no malignant consequences of GVM or risks of severe bleeding. Both brothers have a 50% chance of passing on the condition to their offspring.

The mother did not carry this variant and, unfortunately, father was not available for testing.

DISCUSSION

To understand the inheritance pattern of this condition and how the children have been affected, it is necessary to take a closer look at the genetics of GVMs.

The glomulin gene (*GLMN*) on the short arm of chromosome 1 at 1p21p22 has been shown to be responsible for GVMs by the Brouillard group.^{12 13} It is likely that glomulin has a role in vasculature development, as seen by its high expression in mouse vasculature.¹⁵ This role is significant as in mouse embryos where both *GLMN* copies have a pathogenic variant the embryo is not viable.¹⁶ Glomulin has been shown to have a role in regulating proliferative proteins by binding to Ringbox protein-1, reducing ubiquitination, and also interacting with an F-box protein (Fbw7).¹⁷ It is also involved in transforming growth factor beta (TGF- β) signalling which regulates endothelial cell migration and proliferation.¹³

In families where *GLMN* contains loss of function variants, there is a tendency for the development of GVMs¹³ presumably through unregulated proliferation.¹⁵ At least 162 such families have been identified, with at least 40 different variants.¹⁸ Eighty seven of these cases are explained by one of 16 changes.

Interestingly, the single pathogenic variant in *GLMN* alone does not automatically give rise to GVMs. It shows variable expressivity, with some carriers of the variants having very

mild symptoms compared with those more severely affected, even within the same family. In a study of 381 patients with *GLMN* variants, a high but incomplete penetrance of 90% was demonstrated with 37 patients being completely unaffected despite carrying the gene with a known pathogenic variant.¹⁸ Studies have now been able to find a series of somatic variants affecting the second *GLMN* allele. This concept that a second, tissue-level change is needed for phenotypic expression of GVM is known as the 'two-hit' hypothesis.^{13 18} The stage in development of occurrence of the second change, as well as angiogenic activity locally could contribute to the variable expressivity.¹⁸

The development of cutaneomucosal venous malformations, sporadic venous malformations and blue rubber bleb nevus syndrome are all due to variants in the *TEK* gene located on 9p21-22 (see table 1). This gene produces the tyrosine kinase receptor TIE2 which is involved in normal angiogenesis through binding with angiopoietins.

Cutaneomucosal vascular malformations are inherited in an autosomal dominant pattern with a high degree of penetrance.¹⁸ Alterations in germline *TEK* have been shown to be responsible for cutaneomucosal vascular malformations; at times this is associated with a second somatic alteration.¹⁹ The presence of the second variant does not appear to have any effect on phenotype.²⁰

Sporadic venous malformations have now been shown to occur as a result of somatic changes in *TEK*, without germline pathogenic variants.¹⁹ In unifocal sporadic lesions one pathogenic variant occurs, where there are multiple lesions there has often been an earlier somatic change in a progenitor cell followed by a second somatic change in the same allele. The Soblet group classed this as an initial somatic mosaicism followed by a second mosaic hit, with 1%–5% of the initial mutation being detected in blood samples as opposed to just tissue samples for the other variants.²⁰ They also discovered that in 20% of unifocal lesions, a somatic change in a different gene was responsible, *PIK3CA*.²¹ These lesions were clinically similar to those occurring due to variants in the *TEK/TIE2* pathway.

The process in blue rubber bleb nevus syndrome is that there is a double hit in one somatic *TEK* allele (T1105N-T1106P) thought to both occur at the same time in an earlier endothelial progenitor cell.²⁰

The relevance of understanding the gene involved as well as its place in the molecular signalling is that this could open new doors for targeted therapy. The use of sirolimus in TIE2 mediated venous malformations has had some success to date.²² The use of such molecular targeted treatments for GVMs is an exciting possibility.

Learning points

- ▶ In assessing patients with multiple venous malformations, glomuvenous malformations (GVMs) need to be considered as the condition is relatively benign compared with blue rubber bleb or cutaneomucosal malformations and lacks the complications of severe bleeding or coagulopathy.
- ▶ Diagnosis via a genetic blood test can avoid long-term surveillance testing and anxiety around the risk of gastrointestinal bleeding.
- ▶ GVMs are caused by a pathogenic variant in both the germline and somatic copies of the same gene, this is an example of the 'two-hit' hypothesis in action.

Contributors MHM collated clinical data and wrote the manuscript, MB supervised the write-up. NT provided the MRI and clinical history of the initial presentation to radiology. All authors reviewed the write up and approved the first submitted draft. MB provided insights into the methodology of testing the patients in the case report.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained from parent(s)/guardian(s).

Provenance and peer review Not commissioned; externally peer reviewed.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

REFERENCES

- 1 Mortimer PS, Hay RJ. Blood and Lymphatic Vessel Disorders chapter. In: *Oxford textbook of medicine*. 6th Ed, 2020.
- 2 Nguyen H-L, Boon LM, Vikkula M. Vascular anomalies caused by abnormal signaling within endothelial cells: targets for novel therapies. *Semin Intervent Radiol* 2017;34:233–8.
- 3 Sadick M, Müller-Wille R, Wildgruber M, et al. Vascular anomalies [part I]: classification and diagnostics of vascular anomalies. In: *InRöFo-Fortschritte auf dem Gebiet Der Röntgenstrahlen und Der bildgebenden Verfahren*. Georg Thieme Verlag KG, 2018: 190. 825–35.
- 4 ISSVA classification for vascular anomalies © [Approved at the 20th ISSVA Workshop, Melbourne, April 2014, 2018. Available: <https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf> [Accessed 22 Jan 2021].
- 5 Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. *Arch Dermatol* 2004;140:971–6.
- 6 Wetzel-Strong SE, Detter MR, Marchuk DA. The pathobiology of vascular malformations: insights from human and model organism genetics. *J Pathol* 2017;241:281–93.
- 7 Mravic M, LaChaud G, Nguyen A, et al. Clinical and histopathological diagnosis of glomus tumor: an institutional experience of 138 cases. *Int J Surg Pathol* 2015;23:181–8.
- 8 Domp Martin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. *Phlebology* 2010;25:224–35.
- 9 Boon LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies. *Clin Plast Surg* 2011;38:7–19.
- 10 Domp Martin A, Ballieux F, Thibon P, et al. Elevated D-dimer level in the differential diagnosis of venous malformations. *Arch Dermatol* 2009;145:1239–44.
- 11 Online Mendelian inheritance in man, OMIM®. Johns Hopkins University, Baltimore, MD. date last edited: 23.02.2016. Available: <https://www.omim.org/> [Accessed 22 Jun 2021].
- 12 Boon LM, Brouillard P, Irrthum A, et al. A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21-22. *Am J Hum Genet* 1999;65:125–33.
- 13 Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). *Am J Hum Genet* 2002;70:866–74.
- 14 Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. *Genet Med* 2015;17:405–24.
- 15 McIntyre BAS, Brouillard P, Aerts V, et al. Glomulin is predominantly expressed in vascular smooth muscle cells in the embryonic and adult mouse. *Gene Expr Patterns* 2004;4:351–8.
- 16 Brouillard P, Vikkula M. Genetic causes of vascular malformations. *Hum Mol Genet* 2007;16 Spec No. 2:R140–9.
- 17 Tron AE, Arai T, Duda DM, et al. The glomuvenous malformation protein Glomulin binds Rbx1 and regulates Cullin ring ligase-mediated turnover of Fbw7. *Mol Cell* 2012;46:67–78.
- 18 Brouillard P, Boon LM, Revencu N, et al. Genotypes and phenotypes of 162 families with a glomulin mutation. *Mol Syndromol* 2013;4:157–64.
- 19 Limaye N, Wouters V, Uebelhoefer M, et al. Somatic mutations in angiotensin receptor gene TEK cause solitary and multiple sporadic venous malformations. *Nat Genet* 2009;41:118–24.
- 20 Soblet J, Kangas J, Nätyki M, et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (Tie2) mutations. *J Invest Dermatol* 2017;137:207–16.
- 21 Limaye N, Kangas J, Mendola A, et al. Somatic activating PIK3CA mutations cause venous malformation. *Am J Hum Genet* 2015;97:914–21.
- 22 Kangas J, Nätyki M, Eklund L. Development of molecular therapies for venous malformations. *Basic Clin Pharmacol Toxicol* 2018;123 Suppl 5:6–19.

Copyright 2022 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow